Semglot was studied in a trial in children with obesity in a joint clinical study involving researchers from five countries, the drug showed efficacy in the treatment of obesity in children aged 6-11 years. 167 children participated in the study: 112 received Semlutad, 55 received placebo. Treatment lasted 104 weeks, followed by a seven-week withdrawal period; Both groups were also consulted by a dietician about lifestyle changes. At 68 weeks, there was a decrease in body mass index in 79% of the children taking sediments and 23% who received placebo. Among the side effects, the researchers noted a decrease in growth in children on the drug. The report on the STEP Young clinical trial said that over 68 weeks, the average body mass index of those taking Semlutad decreased by 13.5%, while in the placebo group it increased by 2.7%. According to this report, prediabetes went undiagnosed in 93% of children treated with smaglutide, compared to 56% in the placebo group; some participants developed nausea, vomiting, and diarrhea.